Dapagliflozin-Induced Serum Magnesium Changes and Lipid Profiles in Asymptomatic Heart Failure

Serum Magnesium Changes Induced by Dapagliflozin in Asymptomatic Heart Failure Patients and Their Association with Lipid Profiles: A Retrospective Study Using DAPA-EAT Samples

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050240257

Enrollment

186

Registered

2025-01-31

Start date

2025-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asymptomatic Heart Failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were enrolled in the DAPA-EAT study at Wakayama Medical University Hospital and were followed up for 24 weeks.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they meet any of the following criteria: 1)Patients with a history of taking SGLT2 inhibitors. 2)Patients with a history of hypersensitivity to dapagliflozin. 3)Patients with type 1 diabetes. 4)Patients with significant anemia (hemoglobin 150 IU/L, ALT > 150 IU/L, ALP > 300 U/L). 6)Patients with severe renal failure (eGFR < 30 ml/min/1.73m2). 7)Patients receiving systemic steroid therapy (local administration is allowed). 8)Patients with a history of alcohol or drug abuse within the past 3 months. 9)Patients who had a urinary or genital tract infection within the past 2 weeks. 10)Patients with severe aortic valve stenosis. 11)Patients with symptomatic coronary artery disease. 12)Patients scheduled for cardiovascular surgery within 24 weeks after enrollment. 13)Patients with systolic blood pressure < 90 mmHg. 14)Patients who cannot undergo contrast-enhanced CT due to contrast agent allergies. 15)Pregnant or lactating women, or those planning to become pregnant. 16)Patients whom the principal investigator, responsible investigator, or sub-investigator deems inappropriate for study participation. 17)Patients who express their refusal to participate after the public disclosure of study information.

Design outcomes

Primary

Measure	Time frame
Change in serum magnesium levels from baseline to 24 weeks after enrollment	—

Secondary

Measure	Time frame
Association between changes in serum magnesium levels (from baseline to 24 weeks) and the following parameters: (1)Change in epicardial adipose tissue (EAT) volume (2)Change in LDL cholesterol (LDL-C) levels (3)Change in non-HDL cholesterol (non-HDL-C) levels (4)Change in triglyceride (TG) levels	—

Contacts

Public ContactKosuke Osawa

Wakayama Medical University

k_osawa@wakayama-med.ac.jp+81-73-441-0639

Outcome results